Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00783796 · ClinicalTrials.gov registry record · NA
SPIRIT Small Vessel Registry
A NA study, sponsored by Abbott Medical Devices.
- Terminated
- Registry status
- NA
- Development phase
- 150
- Enrollment target
NCT00783796 is a NA study that was terminated before completion, run by Abbott Medical Devices. The registered enrollment target is 150 participants.
The verdict
NCT00783796, a NA study, was terminated before completion, sponsored by Abbott Medical Devices.
- TERMINATED
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
Study Summary
To evaluate the safety and effectiveness of the 2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in improving coronary luminal diameter in subjects with ischemic heart disease due to a maximum of two de novo native coronary artery lesions in small vessels, each in a different epicardial vessel.
Interventions
- DEVICE 2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2008-10 |
| Est. Completion | 2013-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00783796
The ClinicalTrials.gov registry entry for NCT00783796 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System is the first listed.
NCT00783796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00783796 about?
NCT00783796 is a clinical study titled "SPIRIT Small Vessel Registry". To evaluate the safety and effectiveness of the 2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in improving coronary luminal diameter in subjects with ischemic heart disease due to a maximum of two de novo native coronary artery lesions in small vessels, each in a diffe...
What is the current status of trial NCT00783796?
This trial is currently terminated. It is a NA study. The enrollment target is 150 participants. The study started on 2008-10. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00783796?
The interventions under investigation include: 2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System (DEVICE).
Who is sponsoring clinical trial NCT00783796?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.